

10 November 2023

ASX Announcement

Island receives R&D tax refund for FY2023

MELBOURNE Australia, 10 November 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") is pleased to announce that it has received \$386,345 via the Research and Development (R&D) Tax Incentive from the Australian Taxation Office (ATO) for the financial year ended 30 June 2023.

Island's R&D refund is a valuable and supportive source of funding for the Company's lead asset, ISLA-101, which is being repurposed for the prevention and treatment of dengue and other mosquito (or vector) borne diseases.

Island's CEO and Managing Director, Dr David Foster said: "Running the ISLA-101 Single Ascending Dose study in Australia has enabled access to this R&D Tax Incentive. It is welcome to have access to this non-dilutive funding to feed back into our clinical program.

The Australian Government's R&D Tax Incentive plays a vital role in supporting local companies like Island to innovate and grow. Investing in medical and scientific R&D not only stimulates industry but enables Australian companies like us to solve critical unmet health needs."

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.